Ovarian epithelial cancer

Common Name(s)

Ovarian epithelial cancer

Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases ({6:Chi et al., 2001}). These typical features relate to the biology of the disease, which is a principal determinant of outcome ({1:Auersperg et al., 2001}). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium ({44:Stany et al., 2008}; {43:Soslow, 2008}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian epithelial cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian epithelial cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Ovarian epithelial cancer" returned 682 free, full-text research articles on human participants. First 3 results:

Recurrence season impacts the survival of epithelial ovarian cancer patients.
 

Author(s): Xiao-Hui Liu, Ya-Nan Man, Xiong-Zhi Wu

Journal: Asian Pac. J. Cancer Prev.. 2014 ;15(4):1627-32.

 

Several studies indicated that the diagnosis season affects the prognosis of some cancers, such as examples in the prostate, colon and breast This retrospective study aimed to investigate whether the diagnosis and recurrent season impacts the prognosis of epithelial ovarian cancer patients.

Last Updated: 19 Mar 2014

Go To URL
A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
 

Author(s): Koichi Yoneyama, Hideki Konishi, Tetsuro Yahata, Kazuyuki Fujita, Yoichi Aoki, Daisuke Doi, Takashi Matsushima, Shoji Kodama, Shigeru Honma, Hisamori Kato, Hiroki Nakayama, Seiryu Kamoi, Hirobumi Asakura, Toshiyuki Takeshita, Kenichi Tanaka

Journal: J Nippon Med Sch. 2014 ;81(1):28-34.

 

The objective of this multicenter phase II study was to evaluate the effects of biweekly paclitaxel and carboplatin combination chemotherapy on response rate and toxicities in patients with epithelial ovarian cancer.

Last Updated: 11 Mar 2014

Go To URL
Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
 

Author(s): Yu Wu, Xian Zhang, Li Lin, Xiao-Ping Ma, Ying-Chun Ma, Pei-Shu Liu

Journal: Asian Pac. J. Cancer Prev.. 2014 ;15(3):1171-6.

 

The tumor suppressor gene, Ras-association domain family (RASSF)2A, is inactivated by promoter hypermethylation in many cancers. The current study was performed to evaluate the methylation status of RASSF2A in epithelial ovarian cancer (EOC) tissues and plasma, and correlations with ...

Last Updated: 10 Mar 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Ovarian epithelial cancer" returned 61 free, full-text review articles on human participants. First 3 results:

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
 

Author(s): Samuel J Klempner, Andrea P Myers, Gordon B Mills, Shannon N Westin

Journal: Expert Opin Pharmacother. 2013 Nov;14(16):2171-82.

 

Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an exquisitely chemo-sensitive disease with response rates of over 75% in the upfront setting. Despite this, due to high rates ...

Last Updated: 9 Oct 2013

Go To URL
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
 

Author(s): Xiaoxiang Chen, Jing Zhang, Zhihong Zhang, Hongxia Li, Wenjun Cheng, Jinsong Liu

Journal: Hum. Pathol.. 2013 Nov;44(11):2373-84.

 

Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights ...

Last Updated: 15 Oct 2013

Go To URL
Recurrent epithelial ovarian cancer: an update on treatment.
 

Author(s): Olivia W Foley, J Alejandro Rauh-Hain, Marcela G del Carmen

Journal: Oncology (Williston Park, N.Y.). 2013 Apr;27(4):288-94, 298.

 

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges ...

Last Updated: 20 Jun 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
 

Status: Recruiting

Condition Summary: Ovarian Neoplasms; Ovarian Epithelial Cancer

 

Last Updated: 12 May 2014

Go to URL
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
 

Status: Recruiting

Condition Summary: Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer

 

Last Updated: 18 Sep 2014

Go to URL
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
 

Status: Recruiting

Condition Summary: Ovarian Neoplasms; Ovarian Cancer (OvCa); Ovarian Epithelial Cancer

 

Last Updated: 12 May 2014

Go to URL